Free Trial

Leerink Partnrs' Rating of Cytokinetics on 8/15/2023

On August 15, 2023, Leerink Partnrs updated its outlook on Cytokinetics (NASDAQ:CYTK) with the action "Reiterated Rating", keeping a "Outperform" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.